Literature DB >> 8557986

Herpes simplex virus type 1-mediated up-regulation of IL-12 (p40) mRNA expression. Implications in immunopathogenesis and protection.

S Kanangat1, J Thomas, S Gangappa, J S Babu, B T Rouse.   

Abstract

In this report we investigated whether induction of IL-12 occurs in response to herpes simplex virus (HSV) infection of the mouse eye, which may serve to regulate the nature of the subsequent immune response. The data show early induction and continued maintenance of IL-12 (p40) mRNA in the cornea and draining lymph node upon ocular infection with HSV. Using a very sensitive radioimmunoassay technique, IL-12 (p40) protein also was detected in the cornea upon ocular HSV infection. Unfractionated splenocytes and enriched populations of dendritic cells, macrophages, and neutrophils all responded to HSV infection in vitro by up-regulating the expression of IL-12 (p40) mRNA. However, cultured corneal cells failed to generate IL-12 (p40) upon exposure to HSV. The data indicate that inflammatory cells that infiltrate the cornea in response to HSV-1 infection are the main source of IL-12 in the eye. Our results are consistent with the hypothesis that IL-12 induction in the eye acts as a triggering event that biases HSV-specific immunity to a type 1 T cell response, which, in the environment of the eye, culminates in an immunopathologic disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557986

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients.

Authors:  Afsar Rahbar; Madeleine Cederarv; Nina Wolmer-Solberg; Charlotte Tammik; Giuseppe Stragliotto; Inti Peredo; Olesja Fornara; Xinling Xu; Mensur Dzabic; Chato Taher; Petra Skarman; Cecilia Söderberg-Nauclér
Journal:  Oncoimmunology       Date:  2015-08-24       Impact factor: 8.110

2.  Role of interleukin-12 in primary influenza virus infection.

Authors:  J M Monteiro; C Harvey; G Trinchieri
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 3.  Experimental investigation of herpes simplex virus latency.

Authors:  E K Wagner; D C Bloom
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

4.  Effects of methylprednisolone on intracellular bacterial growth.

Authors:  G U Meduri; S Kanangat; M Bronze; D R Patterson; C U Meduri; C Pak; E A Tolley; D R Schaberg
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

5.  Interleukin-12- and gamma interferon-dependent innate immunity are essential and sufficient for long-term survival of passively immunized mice infected with herpes simplex virus type 1.

Authors:  S Vollstedt; M Franchini; G Alber; M Ackermann; M Suter
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Effects of cytokines and endotoxin on the intracellular growth of bacteria.

Authors:  S Kanangat; G U Meduri; E A Tolley; D R Patterson; C U Meduri; C Pak; J P Griffin; M S Bronze; D R Schaberg
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

7.  A novel p40-independent function of IL-12p35 is required for progression and maintenance of herpes stromal keratitis.

Authors:  Gregory M Frank; Sherrie J Divito; Dawn M Maker; Min Xu; Robert L Hendricks
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-05       Impact factor: 4.799

Review 8.  Animal models of herpes simplex virus immunity and pathogenesis.

Authors:  Christina M Kollias; Richard B Huneke; Brian Wigdahl; Stephen R Jennings
Journal:  J Neurovirol       Date:  2014-11-12       Impact factor: 2.643

Review 9.  Immunopathogenesis of herpetic ocular disease.

Authors:  J Thomas; B T Rouse
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

10.  Herpes simplex virus type 2 induces rapid cell death and functional impairment of murine dendritic cells in vitro.

Authors:  C A Jones; M Fernandez; K Herc; L Bosnjak; M Miranda-Saksena; R A Boadle; A Cunningham
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.